Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Sergio Rodriguez-Rodriguez, Rebeca Bailen, Keven Vachon, Brittany Salter, Christopher Lemieux, Kareem Jamani, Mohamed Elemary, Sylvie Lachance, Jonas Mattsson, Kylie Lepic, Amani Ahmed, Jennifer White, Felipe Peña-Muñoz, Juan Alberto Martín González, Jose Antonio Perez Simon, Matthias Fante, Daniel Wolff, Mi Kwon, Dennis Kim

Blood (2025) 146 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2025-4239

Published: 2025

Journal Articles

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Blood (2025) 146 (Supplement 1): 964.

https://doi.org/10.1182/blood-2025-964

Published: 2025

Journal Articles

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Blood (2025) 146 (Supplement 1): 3862.

https://doi.org/10.1182/blood-2025-3862

Published: 2025

Journal Articles

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Sergio Rodriguez-Rodriguez, Nihar Desai, Brittany Salter, Amani Ahmed, Mohamed Elemary, Jonas Mattsson, Kylie Lepic, Jennifer White, Dennis Kim

Blood (2025) 146 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2025-2470

Published: 2025

Journal Articles

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Eshrak Al-Shaibani, Jonas Mattsson, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Hanan Alkhaldi, Muhned Alhumaid, Ayman Saad, Francesca Biavasco, Robert Zeiser, Dennis Kim

Blood (2025) 146 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2025-4273

Published: 2025

Journal Articles

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Blood (2025) 146 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2025-4284

Published: 2025

Journal Articles

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Blood (2025) 146 (Supplement 1): 6031.

https://doi.org/10.1182/blood-2025-6031

Published: 2025

Journal Articles

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

Blood (2025) 146 (Supplement 1): 6025.

https://doi.org/10.1182/blood-2025-6025

Published: 2025

Journal Articles

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Blood (2024) 144 (Supplement 1): 7418.

https://doi.org/10.1182/blood-2024-206153

Published: 2024

Journal Articles

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Blood (2024) 144 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2024-211183

Published: 2024

Journal Articles

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Blood (2024) 144 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2024-194441

Published: 2024

Journal Articles

Real-World Efficacy of Belumosudil in Treating Fibrotic Symptom Burden in Chronic Gvhd: Modified Lee Symptom Score Assessment after Multiple Treatment Failures

Nihar Desai, Arjun Law, Christopher Lemieux, Keven Vachon, Kareem Jamani, Mohamed Elemary, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2024-211615

Published: 2024

Journal Articles

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Irwin Walker, Uday Deotare, Mohamed Elemary, Mahmoud Elsawy, Genevieve Gallagher, David Kliman, Tony Panzarella, Nada Hamad, Kirk R. Schultz, Jan Storek, Kristjan Paulson

Blood (2024) 144 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2024-198798

Published: 2024

Journal Articles

Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD

Yomna Eissa, Hyeoung-Joon Kim, Joon Ho Moon, Robert Zeiser, Francesca Biavasco, Christopher Lemieux, Mohamed Elemary, Varun Mehra, Mili Shah, Ahmed Alotaibi, Yu Cai, Xianmin Song, Jae-Sook Ahn, Sang Kyun Sohn, Mohsen Al Zahrani, Muhned Alhumaid, Hee-Je Kim, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 778.

https://doi.org/10.1182/blood-2024-208622

Published: 2024

Journal Articles

Can Optical Genome Mapping Replace Bone Marrow Biopsies in Acute Myeloid Leukemia?

Logan Hahn, John DeCoteau, Karen Mochoruk, Gabriela Tanumihardja, Holly Giasson, Ronald Geyer, Waleed Sabry, Mohamed Elemary, Julie Stakiw, Rebecca Ellyn MacKay, Mark Bosch

Blood (2024) 144 (Supplement 1): 5963.

https://doi.org/10.1182/blood-2024-211936

Published: 2024

Journal Articles

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Eshrak Al-Shaibani, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Muhned Alhumaid, Hanan Alkhaldi, Ayman Saad, Francesca Biavasco, Robert Zeiser, Joon Ho Moon, Sang Kyun Sohn, Jonas Mattsson, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2024-211761

Published: 2024

Journal Articles

Retrospective, Multi-Center Analysis of Ruxolitinib Tapering after Successful Treatment of Steroid Refractory Chronic Graft Versus Host Disease

Daniel Levin, Kareem Jamani, Swe Mar Linn, Benoit Yu, Arjun D. Law, Rajat Kumar, Christopher Lemieux, Mohamed Elemary, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4934.

https://doi.org/10.1182/blood-2023-188204

Published: 2023

Journal Articles

Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease

Alistair Murray, Swe Mar Linn, Benoit Yu, Igor Novitzky-Basso, Jonas Mattsson, Mohamed Elemary, Jennifer White, Christopher Lemieux, Kareem Jamani, Dennis Kim

Blood (2022) 140 (Supplement 1): 7662–7663.

https://doi.org/10.1182/blood-2022-164874

Published: 2022

Journal Articles

Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure

Igor Novitzky-Basso, Swe Mar Linn, Jennifer White, Mohamed Elemary, Anargyros Xenocostas, Nada Hamad, Sui Tan, Samantha Culos, Arjun Law, Dennis Dong Hwan Kim

Blood (2021) 138 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2021-151683

Published: 2021

Journal Articles

Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival

Jennifer White, Mohamed Elemary, Swe Mar Linn, Igor Novitzky-Basso, Anargyros Xenocostas, Nada Hamad, Samantha Culos, Sui Tan, Arjun Law, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim, Sr.

Blood (2021) 138 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2021-148859

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Real-World Efficacy of Belumosudil in Treating Fibrotic Symptom Burden in Chronic Gvhd: Modified Lee Symptom Score Assessment after Multiple Treatment Failures

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD

Can Optical Genome Mapping Replace Bone Marrow Biopsies in Acute Myeloid Leukemia?

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Retrospective, Multi-Center Analysis of Ruxolitinib Tapering after Successful Treatment of Steroid Refractory Chronic Graft Versus Host Disease

Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease

Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure

Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only